Abstract
ANTITHROMBIN III (heparin cofactor) is known to inhibit thrombin1 and Factor Xa1–3 (activated Factor X). We have purified antithrombin4 from human plasma by a series of chromatographic and electrophoretic separation techniques. The homogeneity of the final product is demonstrated by disc gel electrophoresis, SDS gel electrophoresis and immunoelectrophoresis4. Using this preparation, we have shown that antithrombin forms a 1 : 1 stoichiometric complex with thrombin which cannot be dissociated with denaturing and reducing agents. Addition of heparin dramatically accelerates the rate of formation of this complex. Complex formation is completely dependent on an interaction between the serine active centre of thrombin and an arginine reactive site of antithrombin. Furthermore, ε-amino lysyl groups of antithrombin serve as binding sites for the highly negatively charged heparin. Based on these data and other evidence, we have proposed that heparin acts to accelerate inhibitor function by binding to antithrombin and inducing an allosteric modification in it, which renders the arginine in its reactive site more accessible to the serine in the active centre of thrombin4.
Similar content being viewed by others
References
Dambrose, F. A., Seegers, W. H., and Sedensky, J. A., Thromb. Diath. haemorrh., 26, 1 (1971).
Higgs, R. K., Denson, W. E., and Akman, N., Br. J. Haemat., 19, 283 (1970).
Yin, T. K., and Wessler, S., J. biol. Chem., 246, 3707 (1971).
Rosenberg, R., and Damus, P. S., J. biol. Chem., 248, 6490 (1973).
Kingdon, H. S., Davie, E. W., and Ratnoff, O. D., Biochemistry, 3, 166 (1964).
Amir, J., Pensky, J., and Ratnoff, O. D., J. lab. clin. Med., 79, 106 (1972).
Ratnoff, O. D., and Menzie, C., J. lab. clin. Med., 37, 316 (1951).
Hardisty, R. M., and McPherson, J. C., Thromb. Diath. haemorrh., 7, 215 (1962).
Abildgaard, U., Thromb. Diath. haemorrh., 24, 224 (1970).
Ratnoff, O. D., Pensky, J., Donaldson, V. H., and Amir, J., J. lab. clin. Med., 80, 803 (1972).
Amir, J., Ratnoff, O. D., and Pensky, J., J. lab. clin. Med., 80, 786 (1972).
Hutt, E. D., and Kingdon, H. S., J. lab. clin. Med., 79, 1027 (1972).
Nemerson, Y., and Esnouf, M. P., Proc. nat. Acad. Sci. U.S A., 70, 310 (1973).
Davie, E. W., and Ratnoff, O. D., The Proteins, 3, chap. 16 (Academic Press, N.Y., 1965).
Wuepper, K. D., and Cochrane, C. G., J. exp. Med., 135, 1 (1972).
Gott, U. L., Whitten, J. D., and Dutton, R. C., Science, N.Y., 142, 1297 (1963).
Wong, P. S. L., Merrill, E. W., and Salzman, E. W., Fedn Proc., 28, 441 (1969).
Kirk, J. E., Nature, 184, 369 (1959).
Gore, I., and Larkey, B. J., J. lab. clin. Med., 56, 839 (1960).
McLean, J., Am. J. Physiol., 41, 250 (1916).
Nossel, H. G., The Contact Phase of Blood Coagulation (Blackwell, Oxford, 1964).
Bell, W. N., and Alten, H. G., Nature, 174, 880 (1954).
Rapaport, S. I., Schiffman, S., and Patch, M. J., J. lab. clin. Med., 59, 771 (1961).
Gerandas, M., Thromb. Diath. haemorrh., 4, 56 (1960).
Rosenberg, R. D., and Waugh, D. F., J. biol. Chem., 245, 5049 (1970).
Laurell, C. B., Analyt. Biochem., 15, 45 (1966).
Stanworth, R., Nature, 188, 156 (1960).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DAMUS, P., HICKS, M. & ROSENBERG, R. Anticoagulant Action of Heparin. Nature 246, 355–357 (1973). https://doi.org/10.1038/246355a0
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1038/246355a0
- Springer Nature Limited
This article is cited by
-
Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes
Thrombosis Journal (2023)
-
Standardization of Anti-Xa Assay and its Comparison with Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin Therapy
Indian Journal of Hematology and Blood Transfusion (2023)
-
Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
Cardiology and Therapy (2021)
-
Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers
Clinical Drug Investigation (2019)
-
An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome
Journal of Intensive Care (2018)